This study has analyzed in detail the role of BRAF/ KRAS/ PIK3CA mutation status of particular colorectal tumours on predicting efficient therapeutic treatments with the BRAF and the PI3K inhibitors as well as their rational combination with TRAIL. Here, PIK3CA is linked to colorectal neoplasm.